cobas® eplex system: Resource center

Browse through a variety of resources and learn more about the cobas® eplex system, cobas® eplex BCID and cobas® eplex RP2 Panels*.

Virtual events

How rapid diagnostics can supercharge antimicrobial stewardship programs
How rapid diagnostics can supercharge antimicrobial stewardship programs

Eric Wenzler, PharmD, BCPS, BCIDP, AAHIVP, Assistant Professor, University of Illinois, Chicago

Laboratory analysis of the cobas® eplex BCID for timelier diagnosis of gram-negative and gram-positive bacteremia
Laboratory analysis of the cobas® eplex BCID for timelier diagnosis of gram-negative and gram-positive bacteremia

Sixto M. Leal Jr., MD, PhD, Director of Clinical Microbiology, University of Alabama at Birmingham and Todd McCarty, MD, Infectious Diseases Physician, University of Alabama at Birmingham

The impact of a rapid blood culture identification system on a pediatric institution
The impact of a rapid blood culture identification system on a pediatric institution

Joel E. Mortensen, Ph.D., director of the diagnostic infectious diseases testing laboratories, Cincinnati Children's Hospital

Rapid BCID saved costs and reduced healthcare worker-patient interaction time during the COVID-19 pandemic
Rapid BCID saved costs and reduced healthcare worker-patient interaction time during the COVID-19 pandemic

Breida Boyle, MB.B.Ch.B.A.O, FRCPI, FRCPath(UK), FFPath(RCPI), PG  Dip. HIC (UK), consultant microbiologist, St. James Hospital, Department of Clinical Microbiology, Trinity College Dublin

Implementation, impact, and updating of rapid blood culture identification system in a community hospital network
Implementation, impact, and updating of rapid blood culture identification system in a community hospital network

Kevin M. McNabb, Ph.D., MT, director of microbiology, immunology and molecular testing, New Hanover Medical Center

...
    ...

    Articles

    ...
      ...

      Products

      ...
        ...

        Publications

        * This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. This test has been authorized only for the simultaneous qualitative detection and differentiation of nucleic acid from SARS-CoV-2 and multiple respiratory viral and bacterial organisms and this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

        Some products in the above articles, publications, webinars and more may be referenced as investigational or research use only and now are IVD.